ImageneBio (IMA) Net Income towards Common Stockholders (2020 - 2025)
ImageneBio (IMA) posted Net Income towards Common Stockholders of -$25.6 million for Q3 2025, down 333.15% sequentially from -$5.9 million in Q2 2025, and down 314.58% YoY from $11.9 million in Q3 2024.
ImageneBio (IMA) Net Income towards Common Stockholders (2020 - 2025) Analysis & Trends
ImageneBio has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$25.6 million in Q3 2025.
- Quarterly Net Income towards Common Stockholders fell 314.58% year-over-year to -$25.6 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$40.7 million (up 31.41% YoY) and the FY2024 annual result came in at -$49.2 million, up 27.77% from the prior year.
- Net Income towards Common Stockholders slipped to -$25.6 million in Q3 2025 per IMA's latest filing, from -$5.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$5.9 million in Q2 2025 and troughed at -$2.1 billion in Q2 2022.
- A 5-year average of -$192.4 million and a median of -$19.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders sank 3859.26% in 2022, then soared 99.2% in 2023.
- Over 5 years, Net Income towards Common Stockholders stood at -$30.5 million in 2021, then surged by 47.96% to -$15.9 million in 2022, then retreated by 23.9% to -$19.7 million in 2023, then increased by 11.06% to -$17.5 million in 2024, then slumped by 46.61% to -$25.6 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$25.6 million, -$5.9 million, and -$9.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -25.63 Mn |
| Jun 30, 2025 | -5.92 Mn |
| Mar 31, 2025 | -9.13 Mn |
| Dec 31, 2024 | -17.48 Mn |
| Sep 30, 2024 | -6.18 Mn |
| Jun 30, 2024 | -16.64 Mn |
| Mar 31, 2024 | -19.00 Mn |
| Dec 31, 2023 | -19.65 Mn |
| Sep 30, 2023 | -17.34 Mn |
| Jun 30, 2023 | -17.12 Mn |
| Mar 31, 2023 | -14.22 Mn |
| Dec 31, 2022 | -15.86 Mn |
| Sep 30, 2022 | -1.05 Bn |
| Jun 30, 2022 | -2.14 Bn |
| Mar 31, 2022 | -22.57 Mn |
| Dec 31, 2021 | -30.48 Mn |
| Sep 30, 2021 | -49.38 Mn |
| Jun 30, 2021 | -54.15 Mn |
| Mar 31, 2021 | -121.50 Mn |
| Dec 31, 2020 | -31.52 Mn |